The Company incurs costs associated with restructuring initiatives intended to improve operating performance, profitability, and working capital levels. Actions associated with these initiatives may include improving productivity, workforce reductions, and the consolidation of facilities.

As of September 30, 2026, the Company expects $1.9 million in additional charges from restructuring actions in the next 12 months.

The Company’s restructuring expenses are comprised of the following (in millions):


	Three Months Ended September 30, 2026
	Cost of Revenues		Selling, general and administrative		Total
Severance and employee costs	$	0.2	$	0.6	$	0.8
Total	$	0.2	$	0.6	$	0.8


	Three Months Ended September 30, 2025
	Cost of Revenues		Selling, general and administrative		Total
Severance and employee costs	$	0.4	$	0.6	$	1.0
Total	$	0.4	$	0.6	$	1.0


	Nine Months Ended September 30, 2026
	Cost of Revenues		Selling, general and administrative		Total
Severance and employee costs	$	0.3	$	1.1	$	1.4
Total	$	0.3	$	1.1	$	1.4


	Nine Months Ended September 30, 2025
	Cost of Revenues		Selling, general and administrative		Total
Severance and employee costs	$	0.6	$	0.8	$	1.4
Total	$	0.6	$	0.8	$	1.4

The following table summarizes restructuring expenses for each reportable segment (in millions):


	Three Months Ended September 30, 2026		Three Months Ended September 30, 2025		Nine Months Ended September 30, 2026		Nine Months Ended September 30, 2025

Restructuring expenses:
Nuclear & Safety	$	0.8	$	0.4	$	0.9	$	0.5
Medical	—		0.6		0.3		0.9
Corporate and other	—		—		0.2		—
Total	$	0.8	$	1.0	$	1.4	$	1.4

The following table summarizes the changes in the Company’s accrued restructuring balance for severance and employee costs, which are included in accrued expenses and other current liabilities in the accompanying Condensed Consolidated Balance Sheets (in millions):


Balance at December 31, 2025	$	0.3
Restructuring charges (excluding impairment)	1.4
Payments	(1.2)
Adjustments	—
Balance at September 30, 2026	$	0.5